Navigation Links
ChromaDex Announces Second Quarter 2008 Financial Results
Date:8/12/2008

IRVINE, Calif., Aug. 12 /PRNewswire-FirstCall/ -- ChromaDex Corporation, (OTC Bulletin Board: CDXC) a leader in phytochemical reference standards and contract research, today announced financial results for the second quarter of 2008. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.03 per share for the three months ended June 28, 2008.

As of June 28, 2008, cash, cash equivalents, and marketable securities totaled approximately $2.4 million. Balance sheet cash, cash equivalents and marketable securities includes all but approximately $1.1 million in proceeds from the final closings of the $4.6 million private placement the Company and its subsidiary just concluded.

"The second quarter of 2008 was significant for ChromaDex," said Frank Jaksch (http://www.chromadex.com/AboutCDX/fjaksch.html), CEO and co-founder of ChromaDex. "We successfully completed a reverse merger acquisition of Cody Resources, Inc. a publicly quoted company on the OTCBB. We did this in order to reap the benefits of public ownership including the ability to enhance our visibility with customers and prospective customers and access to potential new avenues for capital formation. Collectively, we believe this better positions ChromaDex to help us grow and expand to meet the significant and growing needs of customers. In the second half of 2008, we will be focused on expanding our range of products and services to the market."

Additional Financial Results & Notes

On a reported basis, ChromaDex recorded revenue during the second quarter of 2008 of $1,198,885 as compared to $997,087 for the same period in 2007. The net loss attributable to common stockholders for the three months ended June 28, 2008, was $621,676 as compared to $113,926 for the same period in 2007. The
'/>"/>

SOURCE ChromaDex Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ChromaDex, Inc. Announces Completion of Reverse Merger With Cody Resources, Inc.
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... (PRWEB) March 05, 2015 LifeCell Dx ... be able to get an Advanced Semen Analysis before ... blaming and guessing are all risk factors for struggling ... woman is the source of the infertility. Infertility is ... Dx has the simplest, least complicated and inexpensive ...
(Date:3/5/2015)... Research Triangle Park, NC (PRWEB) March 05, 2015 ... Entegrion, Inc., announced that Pierre Noel, M.D., Professor ... been elected to the Company’s Board of Directors. ... Mowell said, “We are extremely fortunate to have ... with the country’s leading healthcare organization, join Entegrion’s ...
(Date:3/5/2015)... SAN DIEGO , March 5, 2015  In ... Marketwired in Miami, FL on ... company are both of strong financial health and their ... as clinical research has indicated. Furthermore, Impeto prefers to have ... There are more than 40 articles written ...
(Date:3/4/2015)... PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... , 3.75% Convertible Senior Notes due May 1, ... per $1,000 principal amount or approximately $5.72 per share, effective ... note is adjusted in connection with the regular quarterly dividend ... stockholders who own shares of PDL on March 5, 2015, the ...
Breaking Biology Technology:LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2
... (Nasdaq: NBIX ) announced today that Kevin Gorman, ... Chief Executive,Officer and a member of the Board of ... President and Chief Executive Officer of,Neurocrine and will continue ... "While this was a very difficult decision for ...
... 14 VIRxSYS Corporation, a,privately held company developing ... Corporation, a privately-owned biotechnology company,focused on the manufacture ... have agreed to settle the pending litigation between,the ... and counterclaims,asserted in the lawsuit, which has been ...
... Patients are ... in the U.S., REHOVOT, Israel and NORTH BRUNSWICK, ... ROSG ), a leader,in the development of microRNA-based diagnostics ... with the Henry Ford,Health System in Detroit, Michigan, to ...
Cached Biology Technology:Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer 2VIRxSYS and Lentigen Announce Litigation Settlement 2Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer 2Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer 3Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer 4
(Date:3/3/2015)... 3, 2015 Cryoport, Inc. (OTCBB: ... cryogenic logistics solutions for the life sciences ... cell lines, clinical research organizations, vaccine manufacturers, ... the expansion of its relationship with ... Hutch") Clinical Research Division with the inclusion ...
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes the ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Middle ... Annual estimates and forecasts are provided for the period 2013 ... these markets. Market data and analytics are derived from primary ...
(Date:2/18/2015)... SUNNYVALE, Calif. , Feb. 18, 2015  Cepheid (NASDAQ: ... be speaking at the following conferences, and invited investors to ... Conference, Boston, MA Tuesday, March 3, ... Institutional Investors Conference, Orlando, FL Wednesday, ... Accessing Live Webcasts To access the live webcasts for these ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Cepheid to Webcast Upcoming Financial Presentations 2
... Washington, D.C. (September 14, 2010) -- Because one ... protein molecules is producing good isolated single crystals, improved ... of genomics and pharmaceutical research. Research reported ... fluorescence correlation spectroscopy (FCS) to investigate the processes at ...
... Biological Sciences Research Council,(BBSRC) have discovered key plant enzymes that ... non-edible parts of plants difficult to extract. The findings, published ... , can be used to improve the viability of sustainable ... The team based at the University of Cambridge, and now ...
... genetic study to compare nuclear DNA of endangered Antillean ... as separate subspecies. Belize,s manatees, however, were found to ... long-term genetic viability. The Central American country of ... manatees and is touted by biologists for its potential ...
Cached Biology News:How do your crystals grow? 2Biofuel from inedible plant material easier to produce following enzyme discovery 2Manatee subspecies genetically confirmed, but diversity challenge looms 2Manatee subspecies genetically confirmed, but diversity challenge looms 3
... Perhaps sheer in-house demand is causing shortages in ... antibody. This can cause unwanted distractions, problems and ... for your hard work and endeavour! Bring us ... and market it internationally. We work under ISO ...
... Diluted Antiserum for RIA, Host: Rabbit ... Immunology Products, Host: Rabbit Antigen ... peptide and 1 2 ... (rat) (H-9295) and ([ 1 2 ...
... vaccinia virus is a type I eukaryotic ... superhelical turns (also called right- and left-handed ... of the reaction is a covalently closed, ... superhelical turns. DNA Topoisomerase I does not ...
...
Biology Products: